CG Oncology targets near $1 bln valuation in US IPO | Reuters

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering.

CouponFollow Extension

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO | Reuters

21 hours ago

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering.

reuters.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

21 hours ago

Jan 18, 2024 · US Markets. MRK. CG Oncology targets near $1 bln valuation in US IPO Credit: REUTERS/DADO RUVIC. January 18, 2024 — 06:33 am EST ... Adds details on company's …

nasdaq.com

$1
OFF

UPDATE 1-CG Oncology Targets Near $1 Bln Valuation In US IPO

21 hours ago

Jan 18, 2024 · US Treasury Bonds Rates. ... UPDATE 1-CG Oncology targets near $1 bln valuation in US IPO. Reuters . Thu, Jan 18, 2024, 6:33 AM 1 min read (Adds details on …

yahoo.com

$1
OFF

Cancer Drug Developer CG Oncology Targets Near $1 Bln Valuation …

21 hours ago

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering.

yahoo.com

6%
OFF

UPDATE 2-Cancer Drug Developer CG Oncology Valued At $1.75 …

21 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

yahoo.com

$1
OFF

CG Oncology Targets Near $1 Billion Valuation In US IPO - Yahoo …

21 hours ago

Jan 18, 2024 · The company is developing a therapy for patients with bladder cancer. Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. …

yahoo.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

21 hours ago

Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. The company is developing a therapy for patients...

marketscreener.com

6%
OFF

Cancer Drug Developer CG Oncology Valued At $1.75 Bln In Strong …

21 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up …

reuters.com

$1
OFF

Cancer Drug Developer CG Oncology Targets Near $1 Bln Valuation …

21 hours ago

Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering. (Reporting by Niket Nishant in Bengaluru; Editing by... …

marketscreener.com

$1
OFF

CG Oncology Targets Near $1 Billion Valuation In US IPO

21 hours ago

Jan 18, 2024 · CG Oncology is one of a handful of companies from the healthcare sector looking to list in the coming months, as a market rally on hopes of a soft landing for the economy …

aol.com

$380
OFF

CG Oncology Prices Larger-than-expected $380M IPO In Hopeful …

21 hours ago

Jan 24, 2024 · Cancer drug developer CG Oncology has raised $380 million in an initial public offering than was larger than it expected, a positive sign for a sector that’s struggled to …

biopharmadive.com

$1.75
OFF

CG Oncology, Inc. (CGON) Stock Price, Quote & News - Stock …

21 hours ago

5 days ago · CG Oncology valued at $1.75 bln in strong market debut. CG Oncology CGON.O notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the …

stockanalysis.com

$306
OFF

Drug Developer CG Oncology Targets Up To $306 Mln For Upsized IPO

21 hours ago

Jan 23, 2024 · Adds background, IPO detail in paragraphs 2-6. Jan 23 (Reuters) - Cancer drug developer CG Oncology said on Tuesday it was aiming to raise up to $306 million in its U.S. …

nasdaq.com

$1
OFF

CG Oncology Targets Near $1 Billion Valuation In US IPO

21 hours ago

Jan 18, 2024 · CG Oncology targets near $1 billion valuation in US IPO. 1/18/24 REUTERS 11:15:46 • ... January 18, 2024 (Reuters) -Cancer drug developer CG Oncology said on …

westlaw.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Nasdaq

21 hours ago

Jan 25, 2024 · Cancer drug developer CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as demand for new …

nasdaq.com

96%
OFF

CG Oncology IPO Rockets 96% In Sign Of Pent-up Deal Demand

21 hours ago

Jan 25, 2024 · Irving, Calif.-based CG Oncology's stock (CGON) closed its first day of trading at $37.17 a share, up 95.6% from its $19 IPO price and well above its opening trade of $29 a share.

morningstar.com

$1
OFF

CG Oncology Targets Near $1 Bln Valuation In US IPO

21 hours ago

Jan 18, 2024 · Cancer drug developer CG Oncology said on Thursday it was targeting a valuation of nearly $1 billion for its initial public offering.The company is developing a therapy for …

tradingview.com

6%
OFF

CG Oncology Valued At $1.75 Bln In Strong Market Debut - Yahoo …

21 hours ago

CG Oncology notched up a valuation of $1.75 billion in its market debut on Thursday, after shares of the cancer drug developer rose 52.6% at the open on the Nasdaq.

yahoo.com

FAQs about CG Oncology targets near $1 bln valuation in US IPO | Reuters Coupon?

How much is CG oncology worth?

Jan 25 (Reuters) - Cancer drug developer CG Oncology (CGON.O) notched up a valuation of $1.75 billion in its market debut on Thursday, after its shares jumped 52.6% at the open, as new listings pick up pace. ...

Why did CG Oncology raise $380 million in its IPO?

Cancer drug developer CG Oncology has raised $380 million in an initial public offering. The company sold 20 million shares in its offering — eight million more than it had expected — at $19 apiece, indicating strong demand from investors. ...

Will CG oncology raise $100 million in a public offering?

IRVINE, Calif.-- (BUSINESS WIRE)--CG Oncology Announces Pricing of Upsized Initial Public Offering. CG Oncology, a Phase 3 biotech developing an oncolytic immunotherapy for bladder cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. ...

Does CG oncology have a biotech IPO?

CG Oncology's initial public offering (IPO), the first by a biotech firm this year, sets the stage for other healthcare companies such as KKR-backed BrightSpring Health Services and Moderna-backed Metagenomi. Investment in biotech companies over the past two years has been a fraction of historical levels. ...

Who are CG oncology's biggest shareholders?

Biotech investor ORI Capital and life sciences investor Decheng Capital are its biggest shareholders. CG Oncology is one of a handful of companies from the healthcare sector looking to list in the coming months, as a market rally on hopes of a soft landing for the economy eases pressure on startups looking to go public. ...

When does CG oncology's stock start trading?

CG Oncology’s common stock is expected to begin trading on the Nasdaq Global Select Market on January 25, 2024 under the ticker symbol "CGON." The offering is expected to close on January 29, 2024, subject to the satisfaction of customary closing conditions. ...